HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs is a research paper published in PLoS ONE (2022). On theSindex it has a DataRank of 0. It has been cited 4 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH
Grant: R01 CA251595
NIH
Grant: R01 CA155192
NIH
Grant: R01 CA077474-14S1
NIH
Grant: R21 CA194868
NIH
Grant: T32 CA009135
University of Wisconsin-Madison
Grant: SciMed Graduate Research Scholars Fellowship
University of Wisconsin Carbone Cancer Center
Grant: P30 CA014520
NCI NIH HHS
Grant: R01 CA077474
National Institutes of Health
Grant: 5R21CA194868-02
Toward identification of a family of novel NF-kB inducers
National Institutes of Health
Grant: 5P30CA014520-18
CANCER CENTER SUPPORT
National Institutes of Health
Grant: 5R01CA251595-03
New Multi-Drug Resistance Mechanism in Multiple Myeloma
National Institutes of Health
Grant: 5R01CA155192-02
Enabling NF-kB Signal Transduction Studies in Primary Multiple Myeloma Cells
National Institutes of Health
Grant: 5R01CA077474-12
Regulation of NEMO modifications in radiation-induced NF-kB signaling
National Institutes of Health
Grant: 3T32CA009135-13S1
PREDOCTORAL TRAINING IN EXPERIMENTAL ONCOLOGY
FWCI
0.59
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals